Front Page News
2022 Cure SMA Annual Research Meeting Summaries – Basic Research Sessions
In June, SMA researchers and clinicians from around the world met in Anaheim, CA, for the 2022 Annual SMA Research and Clinical Care Meeting. There […]
Cure SMA Advocacy Campaign Leads to Congressional Support for More SMA Research
Congress has recognized the unmet and new needs of individuals with SMA by including legislative language in must-pass legislation asking the National Institutes of Health […]
Cure SMA to Hold Patient-Led Listening Session with FDA
On Thursday, August 4, 2022, six members of the SMA community will have the opportunity to talk directly with the U.S. Food and Drug Administration […]
Shop New Cure Merch at Our Updated Online Store
Cure SMA is pleased to announce the launch of our newly updated merch store! The merch store features all the most popular Cure SMA t-shirts, […]
Thank You for a Wonderful 2022 Annual SMA Conference!
Thank you to everyone who attended the 2022 Annual SMA Conference at the Disneyland Hotel in Anaheim, California! It was an impactful weekend of opportunities […]
Cure SMA Attends Spring 2022 Conferences to Promote Findings from Industry Collaboration Initiatives
Cure SMA is pleased to announce the participation of scientific leadership in the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13–16, 2022), […]
Check Out Cure SMA’s State of SMA Report
Cure SMA is pleased to announce the launch of its first annual State of SMA report. The purpose of this report is to share highlights […]
Cure SMA Announces Major Newborn Screening Milestone with Addition of Two New SMA Screening States
With today’s newborn screening action by Oregon and New Mexico, Cure SMA has reached a major screening milestone for spinal muscular atrophy (SMA), with 97 […]
SMA Community Update from Novartis Gene Therapies
We are pleased to share a community update on Novartis Gene Therapies’ Clinical Trial Program.
FDA Approves Genentech’s Evrysdi (risdiplam) For Use in Babies Under Two Months with Spinal Muscular Atrophy
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to […]